Galderma Labs Lp patents expiration
1. Aklief patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807708 | GALDERMA LABS LP | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
Jul, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470871 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(2 years from now) | |
| US8227507 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(2 years from now) | |
| US9084778 | GALDERMA LABS LP | Topical compositions containing a retinoid of the oil-in-water emulsion type |
May, 2033
(9 years from now) | |
| US9498465 | GALDERMA LABS LP | Topical compositions in the form of a gel containing a particular solubilized retinoid |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 4, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 2023-10-05
Market Authorisation Date: 04 October, 2019
Treatment: Method of activating rargamma receptor; Topical treatment of acne vulgaris; Treatment of acne vulgaris
Dosage: CREAM;TOPICAL
AKLIEF family patents
2. Differin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8703820 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(6 months ago) | |
| US7838558 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(6 months ago) | |
| US7834060 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders |
Mar, 2023
(6 months ago) | |
| US7868044 | GALDERMA LABS LP | Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid |
Mar, 2023
(6 months ago) | |
| US7737181 | GALDERMA LABS LP | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Aug, 2024
(10 months from now) | |
| US7579377 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Feb, 2025
(1 year, 4 months from now) | |
| US8435502 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers |
Sep, 2026
(2 years from now) | |
| US8709392 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
Sep, 2026
(2 years from now) | |
| US7998467 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
May, 2028
(4 years from now) | |
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 19 June, 2007
Treatment: Treatment of acne; Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
DIFFERIN family patents
3. Epiduo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8241649 | GALDERMA LABS LP | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide |
Dec, 2022
(9 months ago) | |
| US8936800 | GALDERMA LABS LP | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Dec, 2022
(9 months ago) | |
| US8105618 | GALDERMA LABS LP | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide |
Dec, 2022
(9 months ago) | |
| US8809305 | GALDERMA LABS LP | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris |
Dec, 2022
(9 months ago) | |
| US7964202 | GALDERMA LABS LP | Method for treatment of common acne |
Sep, 2024
(10 months from now) | |
| US7820186 | GALDERMA LABS LP | Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Nov, 2025
(2 years from now) | |
| US8445543 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| US8129362 | GALDERMA LABS LP | Combination/association of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| US8080537 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| US8071644 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient
Market Authorisation Date: 08 December, 2008
Treatment: Treatment of acne
Dosage: GEL;TOPICAL
EPIDUO family patents
4. Epsolay patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9868103 | GALDERMA LABS LP | Metal oxide coating of water insoluble ingredients |
Aug, 2028
(4 years from now) | |
| US9687465 | GALDERMA LABS LP | Compositions for the treatment of rosacea |
Nov, 2032
(9 years from now) | |
| US10945987 | GALDERMA LABS LP | Method for providing early onset of action in the treatment of rosacea |
Feb, 2040
(16 years from now) | |
| US10933046 | GALDERMA LABS LP | Method for treatment of rosacea in patients aged 65 years and older |
Feb, 2040
(16 years from now) | |
| US11541026 | GALDERMA LABS LP | Method for treatment of rosacea |
Feb, 2040
(16 years from now) | |
| US11426378 | GALDERMA LABS LP | Method for long-term treatment of rosacea |
Aug, 2040
(16 years from now) | |
| US11628155 | GALDERMA LABS LP | Method for therapeutic treatment of rosacea |
Dec, 2040
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 22, 2025 |
Drugs and Companies using BENZOYL PEROXIDE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older; Topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older
Dosage: CREAM;TOPICAL
EPSOLAY family patents
5. Metrogel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6881726 | GALDERMA LABS LP | Aqueous compositions containing metronidazole |
Feb, 2022
(1 year, 7 months ago) | |
| US7348317 | GALDERMA LABS LP | Aqueous compositions containing metronidazole |
Feb, 2022
(1 year, 7 months ago) | |
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 30 June, 2005
Treatment: Once a day topical treatment of the inflammatory lesions of rosacea
Dosage: GEL;TOPICAL
METROGEL family patents
6. Mirvaso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859551 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2024
(7 months from now) | |
| US8231885 | GALDERMA LABS LP | Compounds, formulations, and methods for ameliorating telangiectasis |
May, 2025
(1 year, 7 months from now) | |
| US8410102 | GALDERMA LABS LP | Methods and compositions for treating or preventing erythema |
May, 2025
(1 year, 7 months from now) | |
| US8426410 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2025
(1 year, 7 months from now) | |
| US7439241 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing rosacea |
Aug, 2025
(1 year, 10 months from now) | |
| US9861631 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(7 years from now) | |
| US8513247 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(7 years from now) | |
| US8513249 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(7 years from now) | |
| US9861632 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(7 years from now) | |
| US8053427 | GALDERMA LABS LP | Brimonidine gel composition |
Jun, 2031
(7 years from now) | |
| US8163725 | GALDERMA LABS LP | Gel compositions and methods of use |
Jun, 2031
(7 years from now) | |
| US10201517 | GALDERMA LABS LP | Brimonidine gel compositions and methods of use |
Jun, 2031
(7 years from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL;TOPICAL
MIRVASO family patents
7. Oracea patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8603506 | GALDERMA LABS LP | Methods of treating acne |
Apr, 2022
(1 year, 5 months ago) | |
| US7211267 | GALDERMA LABS LP | Methods of treating acne |
Apr, 2022
(1 year, 5 months ago) | |
| US10058564 | GALDERMA LABS LP | Methods of treating acne |
Apr, 2022
(1 year, 5 months ago) | |
| US7232572 | GALDERMA LABS LP | Methods of treating rosacea |
Apr, 2022
(1 year, 5 months ago) | |
| US9241946 | GALDERMA LABS LP | Methods of treating acne |
Apr, 2022
(1 year, 5 months ago) | |
| US8470364 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(6 months from now) | |
| US8394406 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(6 months from now) | |
| US8394405 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(6 months from now) | |
| US8709478 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(6 months from now) | |
| US8206740 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Dec, 2025
(2 years from now) | |
| US7749532 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Dec, 2027
(4 years from now) | |
Drugs and Companies using DOXYCYCLINE ingredient
Market Authorisation Date: 26 May, 2006
Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea
Dosage: CAPSULE;ORAL
ORACEA family patents
8. Soolantra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8080530 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(6 months from now) | |
| US8415311 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(6 months from now) | |
| US8470788 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(6 months from now) | |
| US11033565 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(6 months from now) | |
| US8093219 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(6 months from now) | |
| US7550440 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(6 months from now) | |
| US8815816 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(6 months from now) | |
| US9089587 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(10 years from now) | |
| US9233118 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(10 years from now) | |
| US9782425 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(10 years from now) | |
| US10206939 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(10 years from now) | |
| US9233117 | GALDERMA LABS LP | Treatment of inflammatory lesions of rosacea with ivermectin |
Mar, 2034
(10 years from now) | |
Drugs and Companies using IVERMECTIN ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: CREAM;TOPICAL
SOOLANTRA family patents
9. Tri-luma patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8247395 | GALDERMA LABS LP | Topical skin care composition |
Oct, 2022
(11 months ago) | |
| US8653053 | GALDERMA LABS LP | Topical skin care composition |
Oct, 2022
(11 months ago) | |
| US7915243 | GALDERMA LABS LP | Topical skin care composition |
Sep, 2023
(25 days ago) | |
| US7939516 | GALDERMA LABS LP | Topical skin care composition |
Sep, 2023
(25 days ago) | |
Drugs and Companies using FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN ingredient
Market Authorisation Date: 18 January, 2002
Treatment: NA
Dosage: CREAM;TOPICAL
TRI-LUMA family patents
10. Twyneo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617580 | GALDERMA LABS LP | Compositions for topical application comprising a peroxide and retinoid |
Feb, 2028
(4 years from now) | |
| US9868103 | GALDERMA LABS LP | Metal oxide coating of water insoluble ingredients |
Aug, 2028
(4 years from now) | |
| US10653899 | GALDERMA LABS LP | Core stabilized microcapsules, method of their preparation and uses thereof |
Dec, 2030
(7 years from now) | |
| US11071878 | GALDERMA LABS LP | Core stabilized microcapsules, method of their preparation and uses thereof |
Dec, 2030
(7 years from now) | |
| US10420743 | GALDERMA LABS LP | Methods and compositions for the treatment of acne |
Jul, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination (NC) | Jul 26, 2024 |
Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient
Market Authorisation Date: 26 July, 2021
Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older
Dosage: CREAM;TOPICAL
TWYNEO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic